1. What Is the Sepsis Diagnostics Market?
The Sepsis Diagnostics Market encompasses laboratory and point-of-care diagnostic tests, biomarkers, and clinical decision support tools used to identify sepsis, assess its severity, and monitor treatment response. They also stratify sepsis patients for antimicrobial de-escalation and critical care resource allocation. The market includes procalcitonin immunoassay platforms for sepsis diagnosis and antibiotic stewardship and serum lactate analysers for sepsis severity and hypoperfusion assessment. It also includes host response gene expression panels, CRP rapid tests, and multimarker sepsis risk scoring algorithms integrated with laboratory data. These diagnostics are used by emergency physicians, intensivists, and clinical microbiologists in hospital emergency departments and intensive care units. They confirm or exclude bacterial infection as the cause of systemic inflammatory response syndrome and guide antimicrobial prescribing. Market scope covers laboratory sepsis biomarker assays, point-of-care sepsis tests, and clinical decision support tools for sepsis diagnosis and antimicrobial stewardship. It excludes blood culture systems addressed separately and imaging diagnostics used in sepsis source identification.
2. Sepsis Diagnostics Market Size & Forecast
3. Emerging Technologies
- Rapid sepsis multimarker panel development is advancing combined measurement of procalcitonin, CRP, IL-6, and novel host response biomarkers from a single tube in under 30 minutes, providing clinicians with a. Growing emergency physician and.
- Artificial intelligence sepsis early warning integration is advancing machine learning models embedded in hospital electronic health records that continuously analyse vital signs, laboratory trends, and nursing observation data to generate sepsis risk scores that. Growing industry adoption of this technology is motivating development.
- Metabolomics-based sepsis biomarker discovery is advancing untargeted mass spectrometry metabolite profiling of sepsis patient plasma samples to identify novel diagnostic metabolite signatures that distinguish sepsis from non-infectious SIRS, organ failure severity, and treatment. Growing.
- Microfluidic single-biomarker sepsis bedside testing is advancing disposable lateral flow or electrochemical biosensor cartridge formats that measure procalcitonin, CRP, or IL-6 from a fingerstick blood drop in under 5 minutes at the. Growing interest.
Such innovations are driving change across adjacent industries too. Discover more in our Blood Culture Diagnostics Market.
4. Key Market Opportunity
One of the major opportunities in the Sepsis Diagnostics Market is the expansion of PCT-guided antimicrobial stewardship programmes from ICU to general hospital ward settings where systematic procalcitonin monitoring for antibiotic de-escalation has been insufficiently adopted compared with the ICU evidence base. A significant proportion of hospitalised patients on medical wards receiving antibiotic therapy for community-acquired infection could benefit from PCT-guided de-escalation protocols that reduce antibiotic duration and resistance selection pressure, but systematic ward procalcitonin monitoring has not been adopted at most hospitals. PCT-guided antibiotic stewardship implementation in hospital ward settings requires automated PCT reflex testing protocols, electronic prescribing integration with PCT result alerts, and pharmacist-led de-escalation review supported by PCT trend data. Sepsis diagnostics manufacturers that provide ward-based PCT stewardship programme implementation toolkits, electronic health record alert integration modules, and antimicrobial stewardship pharmacist training packages are positioned to expand PCT-guided stewardship adoption from ICU to hospital-wide antimicrobial prescribing.
5. Top Companies in the Sepsis Diagnostics Market
The following organisations hold leading positions in the Sepsis Diagnostics Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Roche Diagnostics (PCT)
- bioMerieux
- Abbott (Lactate)
- Radiometer
- Thermo Fisher Scientific
- Siemens Healthineers
- Inflammatix (IntelliSep)
- Luminex
- Becton Dickinson
- EKF Diagnostics
6. Market Segmentation
The Sepsis Diagnostics Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Biomarker Type | Procalcitonin PCT Immunoassay Platform POC PCT Test Lactate Serum Lactate Analyser POC Lactate Meter C-Reactive Protein High-Sensitivity CRP POC CRP Test Interleukin-6 IL-6 Immunoassay Presepsin sCD14-ST Presepsin Host Response IntelliSep Gene Expression Multiplex Biomarker Multimarker Sepsis Panel |
| By Application | Sepsis Diagnosis ED Sepsis Screening Antimicrobial Stewardship PCT-Guided Antibiotic Severity Assessment ICU Sepsis Severity Therapy Monitoring Treatment Response PCT Prognosis 30-Day Mortality Prediction |
| By End User | Emergency Departments ED Sepsis Protocol Intensive Care Units ICU Sepsis Monitoring Hospital Clinical Laboratories Sepsis Biomarker Lab Primary Care GP Infection Rule-Out |
| By Geography | North America Europe Asia Pacific Latin America Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Sepsis Diagnostics Market trajectory over the forecast period:
Procalcitonin-Guided Antibiotic Stewardship Technology Is Reducing Unnecessary Antibiotic Duration and Total Antibiotic Exposure in Sepsis Patients.Infectious disease physicians and intensivists managing suspected bacterial sepsis patients are using serial procalcitonin measurements to guide antibiotic de-escalation and discontinuation decisions, with PCT-guided stewardship protocols demonstrating 2 to 3 day shorter antibiotic courses. Equivalent clinical outcomes versus standard-of-care in randomised trials. Roche Diagnostics continued commercial development and evidence generation for Elecsys BRAHMS PCT on cobas platforms in 2024, maintaining market leadership in procalcitonin immunoassay for critical care sepsis antibiotic stewardship programmes.
Point-of-Care Lactate Testing Technology Is Enabling Immediate Sepsis Severity Assessment at Triage in the Emergency Department.Emergency nurses and physicians implementing sepsis bundle protocols that require lactate measurement within 1 hour of triage are adopting point-of-care lactate analysers at triage and resuscitation bays that provide bedside results within 2 minutes. This enables immediate hypoperfusion identification and fluid resuscitation initiation without laboratory turnaround delay. Abbott and Radiometer continued commercial development of handheld and near-patient lactate measurement systems for emergency department sepsis triage in 2024. This provides emergency departments with immediate lactate results for Surviving Sepsis Campaign bundle compliance and triage sepsis severity assessment.
Host Gene Expression Sepsis Diagnostics Technology Is Providing Objective Bacterial Versus Viral Infection Differentiation Beyond Biomarker Sensitivity.Emergency physicians evaluating febrile patients with undifferentiated systemic inflammatory response who require a decision on empiric antibiotic prescription are adopting host transcriptomic response tests including Inflammatix IntelliSep. That measure innate immune gene expression patterns distinguishing bacterial from viral infection aetiology with greater specificity than PCT or CRP alone. Inflammatix continued development and commercial expansion of the IntelliSep host response test for emergency department bacterial versus viral infection differentiation in 2024. This generates clinical validation evidence demonstrating improved specificity for antibiotic prescribing decisions in undifferentiated febrile presentations.
For related market intelligence, see the Polymerase Chain Reaction Pcr Diagnostics Market.
8. Segmental Analysis
By biomarker type, procalcitonin dominated the Sepsis Diagnostics Market in 2025, driven by the established PCT immunoassay role as the primary sepsis biomarker for initial diagnosis and PCT-guided antibiotic stewardship in emergency departments and ICUs. Emergency physicians and intensivists continue specifying procalcitonin as the primary sepsis biomarker as the established PCT evidence base for antibiotic stewardship maintains its position as the regulatory standard for hospital infection biomarker testing. Host response gene expression panels are the fastest-growing biomarker type, driven by growing emergency department adoption of transcriptomic sepsis tests providing bacterial versus viral infection differentiation beyond the diagnostic specificity of single protein biomarkers. Emergency physicians are increasing host response panel adoption as IntelliSep and similar transcriptomic tests provide improved specificity for identifying bacterial sepsis requiring antibiotic therapy from viral syndromes mimicking sepsis presentation.
By application, sepsis diagnosis dominated the Sepsis Diagnostics Market in 2025, driven by the high volume of undifferentiated suspected sepsis presentations at emergency departments requiring rapid biomarker-assisted confirmation or exclusion of bacterial infection. Emergency physicians and hospitalists continue generating the highest sepsis diagnostic demand as rapid PCT and CRP results are required to guide immediate antibiotic prescribing or withholding decisions in the large volume of undifferentiated febrile presentations. Antimicrobial stewardship is the fastest-growing application, driven by hospital pharmacist and infectious disease physician adoption of PCT-guided de-escalation protocols using serial procalcitonin measurements to guide antibiotic discontinuation earlier than clinical assessment. Hospital antimicrobial stewardship pharmacists are increasing PCT-guided de-escalation programme implementation as randomised evidence demonstrating shorter antibiotic duration and equivalent outcomes from PCT-guided stewardship creates pressure to adopt systematic PCT monitoring protocols.
9. Regional Analysis
Regional demand patterns across the Sepsis Diagnostics Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America accounted for the largest share of the Sepsis Diagnostics Market in 2025, holding 45.0% of the global market. The region's dominance reflects the large United States hospital emergency department and ICU base generating procalcitonin and lactate testing demand, established Surviving Sepsis Campaign bundle compliance creating systematic sepsis biomarker procurement, and the headquarters of major sepsis biomarker platform developers including Roche and Abbott with North American commercial operations. Growing United States hospital antimicrobial stewardship programme implementation of PCT-guided antibiotic protocols is creating consistent procalcitonin immunoassay and rapid test demand as hospital pharmacist-led stewardship programmes require serial PCT measurements for antibiotic duration guidance. The large United States emergency department base implementing sepsis bundle triage protocols requiring 1-hour lactate measurement and immediate procalcitonin results is generating consistent point-of-care sepsis biomarker testing demand at emergency departments managing high-acuity sepsis presentations.
Highest CAGR Region
Asia Pacific is expected to register the highest CAGR of 12.00% during the forecast period. Growing sepsis awareness in hospital emergency departments and intensive care units in China, India, Japan, South Korea, and Southeast Asia, expanding antimicrobial stewardship programme implementation, and increasing PCT-guided antibiotic de-escalation protocol adoption are creating demand for sepsis diagnostic biomarker tests. Growing Chinese hospital antimicrobial resistance programme investment and expanding PCT and serum lactate testing adoption at Chinese tertiary hospital ICUs and emergency departments as sepsis bundle protocols become standard practice are creating consistent sepsis biomarker test demand. Growing Indian hospital sepsis management programme development and increasing PCT and lactate point-of-care testing adoption at private tertiary hospitals implementing Surviving Sepsis Campaign bundle protocols are creating demand for sepsis diagnostics in the large Indian hospital market.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Sepsis Diagnostics Market was valued at USD 964.89 Mn in 2025 and is projected to reach USD 2,010.71 Mn by 2034, growing at a CAGR of 8.50% over the 2026–2034 forecast period.
The Sepsis Diagnostics Market is projected to grow at a CAGR of 8.50% from 2026 to 2034.
North America accounted for the largest share of the Sepsis Diagnostics Market in 2025, holding 45.0% of the global market.
The leading companies in the Sepsis Diagnostics Market include Roche Diagnostics (PCT), bioMerieux, Abbott (Lactate), Radiometer, Thermo Fisher Scientific, Siemens Healthineers, Inflammatix (IntelliSep), Luminex, Becton Dickinson, EKF Diagnostics.
Procalcitonin-guided antibiotic stewardship technology is reducing unnecessary antibiotic duration and total antibiotic exposure in sepsis patients.
By biomarker type, procalcitonin dominated the Sepsis Diagnostics Market in 2025, driven by the established PCT immunoassay role as the primary sepsis biomarker for initial diagnosis and PCT-guided antibiotic stewardship in emergency departments and ICUs.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.